Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

@article{Koppikar2010EfficacyOT,
  title={Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.},
  author={Priya Koppikar and Omar Abdel-Wahab and Cyrus V. Hedvat and Sachie Marubayashi and Jay Patel and Aviva J Goel and Nicole Kucine and Jeffrey R. Gardner and Andrew P. Combs and Kris Vaddi and Patrick J. Haley and Timothy C. Burn and Mark J Rupar and Jacqueline F. Bromberg and Mark L. Heaney and Elisa de Stanchina and Jordan S. Fridman and Ross L. Levine},
  journal={Blood},
  year={2010},
  volume={115 14},
  pages={
          2919-27
        }
}
The discovery of JAK2 and MPL mutations in patients with myeloproliferative neoplasms (MPNs) provided important insight into the genetic basis of these disorders and led to the development of JAK2 kinase inhibitors for MPN therapy. Although recent studies have shown that JAK2 kinase inhibitors demonstrate efficacy in a JAK2V617F murine bone marrow transplantation model, the effects of JAK2 inhibitors on MPLW515L-mediated myeloproliferation have not been investigated. In this report, we describe… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS

Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms

  • Journal of experimental & clinical cancer research : CR
  • 2019
VIEW 2 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

A phase I/II study of ICNB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis and postPV/ET myelofibrosis [abstract

S Verstovsek, H Kantarjian, A Pardanani
  • Am Soc Clin Oncol
  • 2008

A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis [abstract

S Verstovsek, AD Pardanani, NP Shah
  • Blood (ASH Annual Meeting Abstracts)
  • 2007